Cargando…

Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens

Patients affected by Inflammatory Bowel Disease (IBD) present higher risk for infection and suboptimal response upon vaccination. The immunogenicity of SARS-CoV2 vaccination is still largely unknown in adolescents or young adults affected by IBD (pIBD). We investigated the safety and immunogenicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotugno, Nicola, Franzese, Enrica, Angelino, Giulia, Amodio, Donato, Romeo, Erminia Francesca, Rea, Francesca, Faraci, Simona, Tambucci, Renato, Profeti, Elisa, Manno, Emma Concetta, Santilli, Veronica, Rotulo, Gioacchino Andrea, Pighi, Chiara, Medri, Chiara, Morrocchi, Elena, Colagrossi, Luna, Pascucci, Giuseppe Rubens, Valentini, Diletta, Villani, Alberto, Rossi, Paolo, De Angelis, Paola, Palma, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318731/
https://www.ncbi.nlm.nih.gov/pubmed/35891273
http://dx.doi.org/10.3390/vaccines10071109
_version_ 1784755363137978368
author Cotugno, Nicola
Franzese, Enrica
Angelino, Giulia
Amodio, Donato
Romeo, Erminia Francesca
Rea, Francesca
Faraci, Simona
Tambucci, Renato
Profeti, Elisa
Manno, Emma Concetta
Santilli, Veronica
Rotulo, Gioacchino Andrea
Pighi, Chiara
Medri, Chiara
Morrocchi, Elena
Colagrossi, Luna
Pascucci, Giuseppe Rubens
Valentini, Diletta
Villani, Alberto
Rossi, Paolo
De Angelis, Paola
Palma, Paolo
author_facet Cotugno, Nicola
Franzese, Enrica
Angelino, Giulia
Amodio, Donato
Romeo, Erminia Francesca
Rea, Francesca
Faraci, Simona
Tambucci, Renato
Profeti, Elisa
Manno, Emma Concetta
Santilli, Veronica
Rotulo, Gioacchino Andrea
Pighi, Chiara
Medri, Chiara
Morrocchi, Elena
Colagrossi, Luna
Pascucci, Giuseppe Rubens
Valentini, Diletta
Villani, Alberto
Rossi, Paolo
De Angelis, Paola
Palma, Paolo
author_sort Cotugno, Nicola
collection PubMed
description Patients affected by Inflammatory Bowel Disease (IBD) present higher risk for infection and suboptimal response upon vaccination. The immunogenicity of SARS-CoV2 vaccination is still largely unknown in adolescents or young adults affected by IBD (pIBD). We investigated the safety and immunogenicity of the BNT162B2 mRNA COVID-19 vaccine in 27 pIBD, as compared to 30 healthy controls (HC). Immunogenicity was measured by anti-SARS-CoV2 IgG (anti-S and anti-trim Ab) before vaccination, after 21 days (T21) and 7 days after the second dose (T28). The safety profile was investigated by close monitoring and self-reported adverse events. Vaccination was well tolerated, and short-term adverse events reported were only mild to moderate. Three out of twenty-seven patients showed IBD flare after vaccination, but no causal relationship could be established. Overall, pIBD showed a good humoral response upon vaccination compared to HC; however, pIBD on anti-TNFα treatment showed lower anti-S Ab titers compared to patients receiving other immune-suppressive regimens (p = 0.0413 at first dose and p = 0.0301 at second dose). These data show that pIBD present a good safety and immunogenicity profile following SARS-CoV-2 mRNA vaccination. Additional studies on the impact of specific immune-suppressive regimens, such as anti TNFα, on immunogenicity should be further investigated on larger cohorts.
format Online
Article
Text
id pubmed-9318731
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93187312022-07-27 Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens Cotugno, Nicola Franzese, Enrica Angelino, Giulia Amodio, Donato Romeo, Erminia Francesca Rea, Francesca Faraci, Simona Tambucci, Renato Profeti, Elisa Manno, Emma Concetta Santilli, Veronica Rotulo, Gioacchino Andrea Pighi, Chiara Medri, Chiara Morrocchi, Elena Colagrossi, Luna Pascucci, Giuseppe Rubens Valentini, Diletta Villani, Alberto Rossi, Paolo De Angelis, Paola Palma, Paolo Vaccines (Basel) Article Patients affected by Inflammatory Bowel Disease (IBD) present higher risk for infection and suboptimal response upon vaccination. The immunogenicity of SARS-CoV2 vaccination is still largely unknown in adolescents or young adults affected by IBD (pIBD). We investigated the safety and immunogenicity of the BNT162B2 mRNA COVID-19 vaccine in 27 pIBD, as compared to 30 healthy controls (HC). Immunogenicity was measured by anti-SARS-CoV2 IgG (anti-S and anti-trim Ab) before vaccination, after 21 days (T21) and 7 days after the second dose (T28). The safety profile was investigated by close monitoring and self-reported adverse events. Vaccination was well tolerated, and short-term adverse events reported were only mild to moderate. Three out of twenty-seven patients showed IBD flare after vaccination, but no causal relationship could be established. Overall, pIBD showed a good humoral response upon vaccination compared to HC; however, pIBD on anti-TNFα treatment showed lower anti-S Ab titers compared to patients receiving other immune-suppressive regimens (p = 0.0413 at first dose and p = 0.0301 at second dose). These data show that pIBD present a good safety and immunogenicity profile following SARS-CoV-2 mRNA vaccination. Additional studies on the impact of specific immune-suppressive regimens, such as anti TNFα, on immunogenicity should be further investigated on larger cohorts. MDPI 2022-07-11 /pmc/articles/PMC9318731/ /pubmed/35891273 http://dx.doi.org/10.3390/vaccines10071109 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cotugno, Nicola
Franzese, Enrica
Angelino, Giulia
Amodio, Donato
Romeo, Erminia Francesca
Rea, Francesca
Faraci, Simona
Tambucci, Renato
Profeti, Elisa
Manno, Emma Concetta
Santilli, Veronica
Rotulo, Gioacchino Andrea
Pighi, Chiara
Medri, Chiara
Morrocchi, Elena
Colagrossi, Luna
Pascucci, Giuseppe Rubens
Valentini, Diletta
Villani, Alberto
Rossi, Paolo
De Angelis, Paola
Palma, Paolo
Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens
title Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens
title_full Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens
title_fullStr Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens
title_full_unstemmed Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens
title_short Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens
title_sort evaluation of safety and immunogenicity of bnt162b2 mrna covid-19 vaccine in ibd pediatric population with distinct immune suppressive regimens
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318731/
https://www.ncbi.nlm.nih.gov/pubmed/35891273
http://dx.doi.org/10.3390/vaccines10071109
work_keys_str_mv AT cotugnonicola evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT franzeseenrica evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT angelinogiulia evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT amodiodonato evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT romeoerminiafrancesca evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT reafrancesca evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT faracisimona evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT tambuccirenato evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT profetielisa evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT mannoemmaconcetta evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT santilliveronica evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT rotulogioacchinoandrea evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT pighichiara evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT medrichiara evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT morrocchielena evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT colagrossiluna evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT pascuccigiusepperubens evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT valentinidiletta evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT villanialberto evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT rossipaolo evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT deangelispaola evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens
AT palmapaolo evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens